IS7858A - Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD) - Google Patents

Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)

Info

Publication number
IS7858A
IS7858A IS7858A IS7858A IS7858A IS 7858 A IS7858 A IS 7858A IS 7858 A IS7858 A IS 7858A IS 7858 A IS7858 A IS 7858A IS 7858 A IS7858 A IS 7858A
Authority
IS
Iceland
Prior art keywords
adhd
treatment
composition
Prior art date
Application number
IS7858A
Other languages
English (en)
Inventor
Vincent Edward Groppi, Jr.
Jon Jacobsen Eric
Kenneth Myers Jason
Walter Piotrowski David
Nelsen Rogers Bruce
Patrick Walker Daniel
Gregory Wishka Donn
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of IS7858A publication Critical patent/IS7858A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7858A 2002-12-11 2005-05-23 Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD) IS7858A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (en) 2002-12-11 2003-11-28 Combination for the treatment of adhd

Publications (1)

Publication Number Publication Date
IS7858A true IS7858A (is) 2005-05-23

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7858A IS7858A (is) 2002-12-11 2005-05-23 Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)

Country Status (23)

Country Link
US (1) US20050107425A1 (is)
EP (1) EP1572300A1 (is)
JP (1) JP2006510663A (is)
KR (1) KR20050085538A (is)
CN (1) CN1735441A (is)
AP (1) AP2005003336A0 (is)
AU (1) AU2003283656A1 (is)
BR (1) BR0317229A (is)
CA (1) CA2509142A1 (is)
CO (1) CO5700801A2 (is)
CR (1) CR7868A (is)
EA (1) EA200500783A1 (is)
EC (1) ECSP055852A (is)
HR (1) HRP20050522A2 (is)
IS (1) IS7858A (is)
MA (1) MA27606A1 (is)
MX (1) MXPA05006336A (is)
NO (1) NO20053185L (is)
OA (1) OA12969A (is)
PL (1) PL377552A1 (is)
TN (1) TNSN05158A1 (is)
WO (1) WO2004052461A1 (is)
ZA (1) ZA200504338B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR20100137473A (ko) * 2008-02-19 2010-12-30 아돌로 코포레이션 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (ko) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
EA200500783A1 (ru) 2005-12-29
JP2006510663A (ja) 2006-03-30
CN1735441A (zh) 2006-02-15
MXPA05006336A (es) 2005-08-26
NO20053185L (no) 2005-08-17
HRP20050522A2 (en) 2005-12-31
EP1572300A1 (en) 2005-09-14
CR7868A (es) 2005-07-08
AU2003283656A1 (en) 2004-06-30
CO5700801A2 (es) 2006-11-30
AP2005003336A0 (en) 2005-06-30
ECSP055852A (es) 2005-09-20
KR20050085538A (ko) 2005-08-29
US20050107425A1 (en) 2005-05-19
NO20053185D0 (no) 2005-06-29
ZA200504338B (en) 2006-07-26
TNSN05158A1 (fr) 2007-05-14
BR0317229A (pt) 2005-11-01
MA27606A1 (fr) 2005-11-01
PL377552A1 (pl) 2006-02-06
OA12969A (en) 2006-10-13
WO2004052461A1 (en) 2004-06-24
CA2509142A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
IS7858A (is) Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
IS8267A (is) [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
DK1342881T3 (da) Opskummet syrebehandlingsvæske
IS7806A (is) Ónæmisvaldandi samsetning
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DE60317699D1 (de) Fermentationsverfahren und -zusammensetzungen
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DE502004002801D1 (de) Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
DE10393374D2 (de) Zusammensetzung
DE60305827D1 (de) Polierzusammensetzung
DE60302398D1 (de) Poliervorrichtung
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
NO20042616L (no) Kjolemediumsblanding og kjolesyklusapparatur for anvendelse derav
NO20045554L (no) Fremgangsmate for behandling av diabetes
SE0500163L (sv) Sammansättning
DE50303208D1 (de) Osteosyntheseeinrichtung
IS7166A (is) Notkun annellataðra pýrrólsambanda í meðhöndlun áliðabrjósks- eða neðanbrjósksbeinahrörnun
IS7136A (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
DE60216645D1 (de) Antiulcus pflanzenzusammensetzung(en)
EP1559415A4 (en) Liquid skin protection composition
EP1561467A4 (en) COMPOSITION FOR RECOVERING DAMAGED SKIN
NO20024880L (no) Sammensetning inneholdende fosfat